Companies ›Healthcare ›RLYB.O

RLYB.O — NASDAQ Biotechnology & Life-Science Tools

Rallybio Corp

$15,95

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

84,4M USD

P/E

—

EV / Rev

65,1x

Div yield

—

Op margin

—

ROE

-21,3 %

Net margin

—

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$14,52

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Rallybio Corp is a biotechnology company focused on developing and commercializing novel therapeutics for patients with rare and serious diseases.

Business. Rallybio Corp (RLYB.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

Generated · model-assisted

Sell-side consensus

HOLD1 analysts

0 buy1 hold0 sell

Avg 12m price target—

Analyst recommendations

1 analysts · consensus Hold

Buy0

Hold1

Sell0

12-month price target

—

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

1 analysts · indicative

Ownership→

FMR LLC

largest disclosed fund holder

Profitability→

-21,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning RLYB.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to RLYB.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Rallybio Corp (RLYB.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

AI synthesis

GENERATED

Rallybio Corp has a market capitalization of $75.17 million and a price-to-book ratio of 0.84, indicating that the company is trading at a discount relative to its book value. The company's liquidity position is strong, with a current ratio of 9.77, suggesting that it has sufficient current assets to cover its current liabilities multiple times over. However, the company has no long-term debt, which may limit its ability to leverage its balance sheet for growth opportunities.

The company's profitability metrics are negative, with a return on equity of -21.34% and a return on assets of -19.15%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The operating income and net income are both negative, at -$20.47 million and -$19.03 million, respectively, which is below the industry median for biotechnology companies. The company's EBITDA multiple is negative at -2.73, further highlighting its unprofitable operations.

Rallybio Corp's revenue is not disclosed in the provided data, but the company's operations are concentrated in the biotechnology and medical research industry. The company's geographic exposure is not specified, but it is likely focused on the United States given its listing on the NASDAQ. The company's revenue concentration in a single industry may expose it to sector-specific risks, such as regulatory changes or shifts in research funding.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The company's operating cash flow and free cash flow are both negative, at -$15.46 million and -$18.99 million, respectively, indicating that it is not generating positive cash flow from operations. The company's negative earnings per share (EPS) of -$1.59 and a mean EPS estimate of -$4.60 suggest that it is not expected to become profitable in the near term.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, with no significant dilution sources identified in the provided data. The company's financial structure is relatively simple, with no long-term debt and a low debt-to-equity ratio of 0.0.

Recent events related to Rallybio Corp include analyst estimates that suggest a neutral outlook, with one "hold" recommendation and no strong buy or sell recommendations. The company's financial performance has been consistently negative, with no signs of improvement in the near term. The company's management and board of directors have not disclosed any significant strategic initiatives or partnerships that could drive future growth.

Key takeaways

Rallybio Corp is a biotechnology company with a strong liquidity position but negative profitability metrics.
The company's market capitalization is $75.17 million, and it is trading at a price-to-book ratio of 0.84.
Rallybio Corp has a current ratio of 9.77, indicating a strong ability to meet short-term obligations.
The company's return on equity and return on assets are both negative, at -21.34% and -19.15%, respectively.
Rallybio Corp has no long-term debt, which may limit its ability to leverage its balance sheet for growth.
The company's financial performance is expected to remain negative, with a mean EPS estimate of -$4.60.
**margin_outlook_rationale**: Rallybio Corp's margin outlook is negative due to its consistent negative operating and net income, which is below the industry median for biotechnology companies.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-16

Q4 2025 · Quarter highlights

Revenue $222.0k, +484,2% YoY; Operating income +46,7% YoY.

Revenue$222.0k+484,2 % YoY

Operating income-$6.4M+46,7 % YoY

Net income-$5.9M+47,0 % YoY

Free cash flow-$5.8M+46,9 % YoY

EPS—

Operating cash flow-$29.8M+39,5 % YoY

Financials

Income statement

Revenue$222.0k

Gross profit—

Operating income-$6.4M

Net income-$5.9M

Margins

Gross margin—

Operating margin-2888.3%

Net margin-2636.0%

FCF margin-2634.7%

Balance sheet

Total assets$62.3M

Total liabilities$4.3M

Total equity$58.0M

Cash & equivalents$31.4M

Long-term debt$0.00

Cash flow

Operating cash flow-$29.8M

CapEx—

Free cash flow-$5.8M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $222.0k, +484,2% YoY
▍Operating income +46,7% YoY
▍Net income +47,0% YoY
▍Free cash flow +46,9% YoY
▍Net margin -2636.0%

Valuation TTM

Market price

$15,95

Market cap

$75.2M

Enterprise valueⓘ

$55.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

65.1x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.8x

P / Tangible bookⓘ

0.8x

Tangible book

$89.2M

Net cashⓘ

$19.3M

Current ratioⓘ

9.8

Debt / equityⓘ

0.0

ROAⓘ

-19.1%

ROEⓘ

-21.3%

Cash conversionⓘ

81.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures

Partners4

Abcellera Biologics IncABCL.OPartner95%Source ↗

Johnson & JohnsonJNJ.NPartner95%Source ↗

Recursion PharmaceuticalsRXRX.OPartner95%Source ↗

SANOFISNY.OPartner95%Source ↗

Supply chain

Vendors → RLYB ↔ Partners → Customers · click any node to drill

4 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs RLYB · multiples and returns

IQV—

Iqvia Holdings Inc

$181,94

30,9B USD

P/E

22,7x

— vs self

Div yield

—

— vs self

ROE

21,9 %

+43,2 vs self

CRL—

Charles River Laboratories

$230,87

11,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-4,6 %

+16,8 vs self

MEDP—

Medpace Holdings Inc

$576,00

16,7B USD

P/E

34,4x

— vs self

Div yield

—

— vs self

ROE

75,4 %

+96,7 vs self

ALKS—

Alkermes PLC

$49,53

8,2B USD

P/E

39,8x

— vs self

Div yield

—

— vs self

ROE

8,4 %

+29,7 vs self

PIII—

P3 Health Partners Inc

$10,20

73,8M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

95,3 %

+116,6 vs self

ORGO—

Organogenesis Holdings Inc

$2,38

306,2M USD

P/E

9,0x

— vs self

Div yield

—

— vs self

ROE

8,5 %

+29,9 vs self

NAGE—

Niagen Bioscience Inc

$3,53

281,1M USD

P/E

17,4x

— vs self

Div yield

—

— vs self

ROE

22,7 %

+44,0 vs self

SPRY—

Ars Pharmaceuticals Inc

$5,51

547,1M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-149,9 %

-128,6 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-4,60

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-4,60
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-28,2M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy0

Hold1

Sell0

Strong sell0

Operating income · consensus-28,2M USD

EPS surprise

+65,5 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

ROE-21,3 %Above median

D/E0,00Above median

Cash Conv0,81Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 32 360 sh2 grants2 insiders

MACKAY MARTINDirector · Option (Right to Buy) → Common StockAcquired 18 055 @ $4,45grant · 2026-02-18
HUNT RONALDDirector · Option (Right to Buy) → Common StockAcquired 14 305 @ $4,45grant · 2026-02-18

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Rallybio Corp Market data — financials · 2026-05-29
Rallybio Corp Market data — analyst estimates · 2026-05-29
Rallybio Corp Market data — ESG · 2026-05-29

Ownership & reference

Top holders

FMR LLCInstitutional Investor · as of 2026-03-310,00 %$7M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

Insider activity

Net buying14 buys · 1 sellsnet $4,2M2 insiders · last 365d

ADAR1 Capital Management, LLC10% owner · Common StockBought 10 000 @ $13,98$140K · 2026-05-19
ADAR1 Capital Management, LLC10% owner · Common StockBought 200 @ $13,80$3K · 2026-05-19
ADAR1 Capital Management, LLC10% owner · Common StockBought 6 009 @ $13,98$84K · 2026-05-18
ADAR1 Capital Management, LLC10% owner · Common StockBought 100 @ $13,80$1K · 2026-05-15
ADAR1 Capital Management, LLC10% owner · Common StockBought 200 @ $13,95$3K · 2026-05-15
ADAR1 Capital Management, LLC10% owner · Common StockBought 75 178 @ $14,00$1,1M · 2026-05-13
ADAR1 Capital Management, LLC10% owner · Common StockBought 4 081 @ $13,80$56K · 2026-05-13
ADAR1 Capital Management, LLC10% owner · Common StockBought 800 @ $13,83$11K · 2026-05-12
ADAR1 Capital Management, LLC10% owner · Common StockBought 5 100 @ $14,00$71K · 2026-05-11
ADAR1 Capital Management, LLC10% owner · Common StockBought 25 000 @ $14,00$350K · 2026-05-11
ADAR1 Capital Management, LLC10% owner · Common StockBought 19 900 @ $14,00$279K · 2026-05-11
ADAR1 Capital Management, LLC10% owner · Common StockBought 35 101 @ $14,00$491K · 2026-05-05
ADAR1 Capital Management, LLC10% owner · Common StockBought 116 904 @ $13,97$1,6M · 2026-05-04
ADAR1 Capital Management, LLC10% owner · Common StockBought 3 900 @ $13,90$54K · 2026-05-04
Lieber Jonathan IChief Financial Officer · Common StockSold 789 @ $5,06$4K · 2026-02-23
Lieber Jonathan IChief Financial Officer · Common StockOther 2 500 · 2026-02-18

Short positioning

170.2Kshares short-58.4% vs prior

3.54days to cover

12.3%short of daily vol

6.7Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

RLYB.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 85.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -6.0%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -33.3%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -52.8%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 84.5%Derived (calculated)
Net margin (FY 2025-12-31): -1,046.4%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 125.7%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.07xDerived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 45.3%Derived (calculated)
Return on equity (FY 2025-12-31): -15.5%Derived (calculated)
Return on assets (FY 2025-12-31): -14.4%Derived (calculated)
Current ratio (FY 2025-12-31): 14.50xDerived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 85.0%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -8.6%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 39.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 34.9%Derived (calculated)
Cash & equivalents (annual): USD 31.37MSEC XBRL filing
Shareholders' equity (annual): USD 57.96MSEC XBRL filing
Operating income (annual): USD -33.06MSEC XBRL filing
Revenue (annual): USD 858KSEC XBRL filing
Current assets (annual): USD 61.25MSEC XBRL filing
Shares outstanding (annual): 5.28MSEC XBRL filing
Operating cash flow (annual): USD -29.81MSEC XBRL filing
Total liabilities (annual): USD 4.3MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-01FILING8-K filing →

2026-05-19 00:00 UTCINSIDER14 insider transactions — 2026-05 · net buy $4.2M

2026-05-19INSIDERADAR1 Capital Management, LLC bought 10.0k sh — 10% owner ~$140k

2026-05-19INSIDERADAR1 Capital Management, LLC bought 200 sh — 10% owner ~$3k

2026-05-18INSIDERADAR1 Capital Management, LLC bought 6.0k sh — 10% owner ~$84k

2026-05-15INSIDERADAR1 Capital Management, LLC bought 100 sh — 10% owner ~$1k

2026-05-15INSIDERADAR1 Capital Management, LLC bought 200 sh — 10% owner ~$3k

2026-05-13FILING10-Q filing →

2026-05-13INSIDERADAR1 Capital Management, LLC bought 75.2k sh — 10% owner ~$1.05M

2026-05-13INSIDERADAR1 Capital Management, LLC bought 4.1k sh — 10% owner ~$56k

2026-05-12INSIDERADAR1 Capital Management, LLC bought 800 sh — 10% owner ~$11k

2026-05-11INSIDERADAR1 Capital Management, LLC bought 5.1k sh — 10% owner ~$71k

2026-05-11INSIDERADAR1 Capital Management, LLC bought 25.0k sh — 10% owner ~$350k

2026-05-11INSIDERADAR1 Capital Management, LLC bought 19.9k sh — 10% owner ~$279k

2026-05-05INSIDERADAR1 Capital Management, LLC bought 35.1k sh — 10% owner ~$491k

2026-05-04FILING8-K filing →

2026-05-04INSIDERADAR1 Capital Management, LLC bought 116.9k sh — 10% owner ~$1.63M

2026-05-04INSIDERADAR1 Capital Management, LLC bought 3.9k sh — 10% owner ~$54k

2026-03-31FILING8-K filing →

2026-03-16 17:19 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.2M · Net USD -5.9M

2026-03-16 17:19 UTCEARNINGSAnnual results — FY 2026 Revenue USD 0.9M · Net USD -9.0M

2026-03-16FILING10-K filing →

2026-03-02FILING8-K filing →

2026-02-23 00:00 UTCINSIDER4 insider transactions — 2026-02 2 derivative

2026-02-23INSIDERLieber Jonathan I sold 789 sh — Chief Financial Officer ~$4k

2026-02-18INSIDERLieber Jonathan I transacted 2.5k sh — Chief Financial Officer

2026-02-18INSIDERHUNT RONALD acquired 14.3k sh Option (Right to Buy) — Director

2026-02-18INSIDERMACKAY MARTIN acquired 18.1k sh Option (Right to Buy) — Director

2026-01-29FILING8-K filing →

2026-01-02FILINGDEF 14A filing →

2025-11-06 08:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 0.2M · Net USD 16.0M

2025-11-06FILING10-Q filing →

2025-11-06FILING8-K filing →

2025-08-29FILING8-K filing →

2025-08-07 08:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.2M · Net USD -9.7M

2025-08-07FILING10-Q filing →

2025-05-13 00:00 UTCINSIDER8 insider transactions — 2025-05 8 derivative

2025-05-08 08:00 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.2M · Net USD -9.4M

Showing the 40 most recent of 51 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread